Healthcare InvestmentThe latest Drive cohorts bring together companies working across small molecules, antibodies, gene editing, gene therapy, oncolytic viruses and cell therapy. For a market where the earliest financing remains hard to raise, the program is functioning less as publicity and more as infrastructure to help companies reach the next financing or development milestone.
Jonathan Blake·Sep 6, 2026Invivyd said Elia, a board member since 2022 and current chairman, will now hold both chairman and CEO roles. The leadership change comes as the company prepares for top-line data from a phase 3 study of VYD2311 in adults and adolescents.
Jonathan Blake·Sep 4, 2026 
Biopharmaceutical IndustryAstraZeneca and Ionis Pharmaceuticals’ Wainua posted a hazard ratio of 1.14 in ATTR-CM when given alongside standard of care treatment, a result that Stifel called clearly worse than expected. While monotherapy data showed a 29% improvement in cardiovascular events, the combined picture makes a regulatory path harder to see and may influence how rivals position next-generation programs.
Jonathan Blake·Aug 29, 2026 
Regulatory & PolicyThe recall affects tablets distributed across the U.S. last year and was made with the FDA’s knowledge. The event combines a product quality problem with the disappearance of the company behind it, creating immediate continuity questions for a niche generic medicine.
Jonathan Blake·Aug 27, 2026 
Biopharmaceutical IndustryThe FDA approval covers intravenously infused nipocalimab, sold as Imaavy, for treating patients age 12 and older with warm autoimmune hemolytic anemia. For J&J, the label expansion adds a first-in-disease position in a rare condition while supporting the company’s broader thesis that Imaavy can become a multibillion-dollar immunology product.
Jonathan Blake·Aug 25, 2026 
Healthcare InvestmentTME Pharma said it has entered the final evaluation phase of advanced discussions with two potential partners for NOX-A12, a CCL2 inhibitor also known as olaptesed pegol, in brain cancer. For a company that started the year with 2 million euros ($2.3 million) in the bank, the partnering process is not just strategic positioning but a prerequisite for the next clinical step.
Jonathan Blake·Aug 25, 2026 
Medical TechnologyThe assay detects phosphorylated Tau 217 protein, which has been linked to amyloid plaque buildup in the brain. Commercially, the clearance points to a broader diagnostic pathway that could move Alzheimer’s assessment beyond PET imaging and cerebrospinal fluid testing in selected patients.
Jonathan Blake·Aug 24, 2026 
Regulatory & PolicySTAT reported that the working paper, which has not yet been peer-reviewed, estimates the drop equals about 34 fewer 12-ounce cans of soda per person per year and could reduce type 2 diabetes risk by 2.6% over the next 10 years. The same study also found that recipients redirected up to 39% of the forgone soda spending to other sugary beverages and were more likely to report feeling judged or disrespected.
Jonathan Blake·Aug 24, 2026 
Healthcare InvestmentThe combined company will keep the Ambros name, remain based in San Diego and be led by current Ambros CEO Jay Hagan. Its lead asset, neridronate, is in an ongoing Phase 3 trial in complex regional pain syndrome type 1 and already holds breakthrough therapy, fast track and orphan drug designations from the FDA.
Jonathan Blake·Aug 22, 2026 Regulatory & PolicyMultiple reports said Trump had chosen or was expected to choose Heidi Overton, deputy director of the White House Domestic Policy Council, as the next FDA commissioner. For drug developers and investors, the immediate issue is less the optics of the pick than whether a confirmed commissioner can restore predictability to an agency that has been operating with acting leadership since Marty Makary’s departure in May.
Jonathan Blake·Aug 19, 2026 
Regulatory & PolicyDauphin County’s recent property tax increases offer one local example of a broader fiscal squeeze hitting state and local governments. With public employers often constrained by union expectations, fixed budgets, and political resistance to tax hikes, the story suggests health benefit inflation is becoming a structural policy issue rather than a negotiable line item.
Jonathan Blake·Aug 19, 2026 
Regulatory & PolicyThe plea centers on efforts to keep messages off government systems and away from records requests, according to court documents. While the unnamed company and two other individuals were not identified in the charging documents, one person matched the description of EcoHealth Alliance’s then-president, Peter Daszak, who has not been charged with a crime.
Jonathan Blake·Aug 19, 2026 